Patents by Inventor Jun-Eui Park

Jun-Eui Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Camsylate salts of triazolopyrazine derivatives
    Patent number: 11964979
    Abstract: A camsylate salt of D(+)-10-camphorsulfonic acid and a triazolopyrazine derivative of formula (1), pharmaceutical compositions thereof, methods of making the salt, and therapeutic use thereof:
    Type: Grant
    Filed: June 27, 2022
    Date of Patent: April 23, 2024
    Inventors: Jun Young Choi, Kyung-eui Park, Na Young Kim
  • METHOD OF INHIBITING KINASE BY CAMSYLATE SALTS OF TRIAZOLOPYRAZINE DERIVATIVES
    Publication number: 20240124472
    Abstract: Disclosed are a salt (camsylate salt) of D(+)-10-camphorsulfonic acid and a triazolopyrazine derivative of formula (1), pharmaceutical compositions thereof, methods of making the salt, and therapeutic use thereof:
    Type: Application
    Filed: December 26, 2023
    Publication date: April 18, 2024
    Inventors: Jun Young CHOI, Kyung-eui PARK, Na Young KIM
  • METHOD OF INHIBITING KINASE BY MESYLATE SALTS OF TRIAZOLOPYRAZINE DERIVATIVES
    Publication number: 20240124473
    Abstract: Disclosed are a salt (mesylate salt) of methanesulfonic acid and a triazolopyrazine derivative of formula (1), pharmaceutical compositions thereof, methods of making the salt, and therapeutic use thereof:
    Type: Application
    Filed: December 26, 2023
    Publication date: April 18, 2024
    Inventors: Jun Young CHOI, Kyung-eui PARK, Na Young KIM
  • METHOD OF PREPARING CAMSYLATE SALTS OF TRIAZOLOPYRAZINE DERIVATIVES
    Publication number: 20240124471
    Abstract: Disclosed are a salt (camsylate salt) of D(+)-10-camphorsulfonic acid and a triazolopyrazine derivative of formula (1), pharmaceutical compositions thereof, methods of making the salt, and therapeutic use thereof:
    Type: Application
    Filed: December 26, 2023
    Publication date: April 18, 2024
    Inventors: Jun Young CHOI, Kyung-eui PARK, Na Young KIM
  • Method for preparing dendritic cells with increased specific gene expression, and composition for treating or preventing autoimmune diseases, containing dendritic cells prepared using same
    Patent number: 10350279
    Abstract: The present invention relates to a method for generating semi-mature dendritic cells by treating immature dendritic cells with the auto-antigen, cytokine, and PGE2 as a target for the treatment of autoimmune diseases, particularly rheumatoid arthritis, in which the levels of NR4A2 and/or UBASH3B at gene or protein are increased more than 2-fold compared to the immature dendritic cells In addition, the present invention relates to a cell therapeutic agent for treating or preventing autoimmune diseases, containing the semi-mature dendritic cells as an active ingredient. The present invention increases the therapeutic efficacy on rheumatoid arthritis retaining responsiveness to the same auto-antigen that being used for preparing semi-mature dendritic cells, thereby enabling cell therapy.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: July 16, 2019
    Assignee: JW CREAGENE INC.
    Inventors: Yong-Soo Bae, Jun-Eui Park, Yun-Ju Woo, Jin-Ah Jang
  • METHOD FOR PREPARING DENDRITIC CELLS WITH INCREASED SPECIFIC GENE EXPRESSION, AND COMPOSITION FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES, CONTAINING DENDRITIC CELLS PREPARED USING SAME
    Publication number: 20170209557
    Abstract: The present invention relates to a method for generating semi-mature dendritic cells by treating immature dendritic cells with the auto-antigen, cytokine, and PGE2 as a target for the treatment of autoimmune diseases, particularly rheumatoid arthritis, in which the levels of NR4A2 and/or UBASH3B at gene or protein are increased more than 2-fold compared to the immature dendritic cells In addition, the present invention relates to a cell therapeutic agent for treating or preventing autoimmune diseases, containing the semi-mature dendritic cells as an active ingredient. The present invention increases the therapeutic efficacy on rheumatoid arthritis retaining responsiveness to the same auto-antigen that being used for preparing semi-mature dendritic cells, thereby enabling cell therapy.
    Type: Application
    Filed: June 23, 2015
    Publication date: July 27, 2017
    Inventors: Yong-Soo Bae, Jun-Eui Park, Yun-Ju Woo, Jin-Ah Jang